1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

  • April 2020
  • 204 pages
  • ID: 5404418
  • Format: PDF
  • GlobalData
Up to $9896 off Until Sep 30th 2020


Table of Contents

Search Inside

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration of the macula, which is the oval-shaped area of the retina that is responsible for central vision.AMD is the most common cause of significant irreversible vision loss among the elderly.

Classified by disease severity, AMD can be divided into three distinct stages.These are the early, intermediate, and late types of AMD.

Out of the late forms, there are two further subtypes: dry (dAMD) and wet (wAMD). Dry AMD is evidenced by atrophy of the cells lining the retina, the accumulation of debris and the death of photoreceptors near the center of the fundus.

Wet AMD is characterized by the growth of abnormal blood vessels that disrupt and misalign the layers of the retina, leading to sight loss. Another form late AMD is geographic atrophy (GA), a slowly progressing subtype characterized by cell death and extensive damage to the retinal pigment epithelium which is a layer of cells attached to blood vessels in the choroid.

There is no way to reverse the sight loss caused by AMD although the progression of the disease can be slowed through treatment with intravitreal anti-angiogenic drugs.Commonly used therapy options in the 9MM are Bayer/Regeneron’s Eylea (aflibercept), Roche/Genentech’s Lucentis (ranibizumab) and Roche’s anti-neoplastic agent Avastin (bevacizumab), which is used as an off-label therapy for retinal diseases.

These drugs inhibit vascular endothelial growth factor (VEGF) which is a protein that promotes the growth of new blood vessels, which leak contents onto the macula in the pathophysiology of wet AMD. There are no approved therapies for neither GA nor dAMD.

Geographic atrophy, dry AMD and wet AMD are treated as separate indications in this forecast model although it is possible to have dry AMD in one eye and wet AMD in the second eye.Although severe side effects from anti-VEGF drugs are rare, it is possible for patients to develop ocular inflammation and increased intraocular pressure as well as a temporary worsening of sight loss in the immediate aftermath of an intravitreal injection.

Unmet needs include the desire to reduce the frequency of administration of intravitreal therapies, the need to identify and monitor at earlier stages of disease and to develop therapies for dry AMD and GA.

The analyst estimates that drug sales for AMD in 2018 were approximately $8.6B across the nine major markets (US, France, Germany, Italy, Spain, UK, Japan, China, and Australia). Over the 10-year forecast period, the market is expected to grow to $18.4B at a CAGR of 7.9%. This growth will be driven by the launch of 11 late-stage pipeline products. The two highest selling drugs are expected to be MacuCLEAR’s therapy for dry AMD, MC-1101, and Roche/Chugai’s faricimab, a monoclonal antibody for wet AMD.

Key Highlights
- The AMD market is expected to grow at a CAGR of 7.9% from 2018 to 2028, reaching a global value of $18.4 billion.
- Anti-VEGFs dominate the AMD marketplace, although the frequency of administration of intravitreal injections is burdensome for wet AMD patients. Other unmet needs include the fact that there are no treatments available for dry AMD or GA, lack of early diagnosis, and the fact that there is no way to reverse the sight loss caused by untreated AMD.
- KOLs were satisfied by the anti-angiogenic mechanism of action as a way to control wet AMD, although the invasive route of administration of anti-VEGF therapies is uncomfortable for many patients.
- Clinical trial data is limited for MacuCLEAR’s MC-1101 (dry AMD) and Alkeus Pharma’s ALK-001 (GA), although this is unlikely to be a significant obstacle in generating sales because of the lack of approved therapies for these indications.
- Dobecure, a Spanish biopharmaceutical company are developing ethamsylate, which is a fibroblast inhibitor. This product is being developed to treat both dry and wet AMD. This is the only pipeline product being developed for both late forms of AMD and is expected to launch in the 5EU markets. The product is marketed for hematological conditions and is genericized, limiting sales in comparison to biologics such as fusion proteins and monoclonal antibodies.
- Despite the warning from the American Society of Retina Specialists that Novartis’ Beovu (brolucizumab) was linked to retinal vasculitis in a subset of wet AMD patients, the drug is still expected to become a top-selling marketed product by the end of the forecast period because of its high annual cost of therapy and classification as a longer-acting anti-VEGF therapy.
- Allergan’s abicipar pegol is also a longer-acting anti-VEGF therapy, administered five times a year, as is Roche/Genentech’s faricimab, injected four times a year. Faricimab is expected to launch in all of the 9MM, contributing to its position as the top-selling late-stage pipeline product for wet AMD.
- Apellis Pharma’s first-in-class immunosuppressive therapy APL-2 is expected to generate higher sales than Alkeus Pharma’s GA therapy, ALK-001. This is because complement inhibition is a mechanism of action that has shown efficacy in clinical trials exploring the potential for immunosuppressive techniques to treat geographic atrophy. Furthermore, APL-2, will launch in the US, 5EU, and Australian markets whereas ALK-001 will only launch in the US market during the forecast window.
- Chengdu Kanghong’s Langmu (conbercept) will also become a top-selling marketed product and benefit from a significant increase in sales. This is partially because the drug is more likely to be selected in China for its less expensive annual cost of therapy compared to Eylea and Lucentis. The large Chinese patient population will be a key driver of sales and the drug is also in the pipeline in the US market, expected to launch in 2023. Another low-cost anti-VEGF, which is Roche/Genentech’s Avastin, is widely available across the 9MM. Sales of Avastin will increase in sales at the beginning of the forecast window before the launch of longer-acting anti-angiogenic therapies.
- The sales of Eylea, Lucentis, and Avastin will decline in all of the 9MM due to the emergence of longer-acting therapies and the entry of biosimilars which will erode sales of their branded counterparts.
- A sustained release version of ranibizumab being developed by Roche is expected to become a top-selling drug because the product, administered in the form of an ocular implant is changed after several months and may be selected as a more convenient option for patients in the US and 5EU markets, where the drug is expected to launch in 2021 and 2022, respectively.

Key Questions Answered in This Report

- What were the main drugs used to manage wet AMD in 2018?
- When will the late stage pipeline products launch in each of the 9MM?
- What effect will each of the late-stage pipeline agents have on drug sales in the 9MM?
- Which unmet needs will remain unaddressed in the forecast period?
- What opportunities remain for drug developers?

- Overview of AMD, including the epidemiology, etiology, pathophysiology, symptoms, diagnosis, and the management of wet AMD.
- Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in patient segments including dry AMD, GA, and wet AMD in a dynamic market forecast from 2018 to 2028.
- Topics covered include a competitive assessment of key players in the market, characterization of marketed and pipeline drugs, an examination of unmet needs, and clinical trials in the 9MM.
- Pipeline analysis: Provides a comprehensive analysis of pipeline products including their mechanism of action, route of administration, the patient population(s) for which the product is being developed, and performance of each drug candidate in clinical trials. Candidates in Phase III have been profiled and innovative therapeutic approaches in the early-stage pipeline are also discussed within the report.
- Analysis of the current and future market competition in the global AMD market, with a particular focus on the new drugs being developed for dry AMD and geographic atrophy.
- The report provides an insightful review of industry drivers, barriers and challenges across the 9MM. Each industry trend in relation to AMD is independently researched to provide an extensive qualitative review of its implications.

Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AMD pharmacotherapy market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on